ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
Year: 2001
Type: article
Source: International Journal of Cancer
DOI: 10.1002/ijc.1557
Authors: Neil G. Anderson, Tawhid Ahmad, Kai Chan, Richard Dobson, Nigel J. Bundred
Institution: University of Manchester
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: AstraZeneca, Breast Cancer Campaign
OpenAlex ID: W2071040849